FRANKFURT, March 10 (Reuters) - German COVID-19 vaccine

maker BioNTech on Monday said that its 2025 revenues

would likely fall to between 1.7 billion euros ($1.85 billion)

and 2.2 billion euros, prompting a decline in its share price.

The guidance compares with revenues of 2.75 billion euros

reported for last year and with an average analyst estimate of

about 2.5 billion for 2025, according to LSEG data.

The biotech firm's German traded stock was down 4.1% at 1110

GMT.

($1 = 0.9213 euros)

(Reporting by Ludwig Burger, editing by Thomas Seythal)